Pacer Advisors Inc. Grows Stock Holdings in Amphastar Pharmaceuticals, Inc. $AMPH

Pacer Advisors Inc. increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2,864.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 177,744 shares of the company’s stock after buying an additional 171,748 shares during the period. Pacer Advisors Inc. owned about 0.39% of Amphastar Pharmaceuticals worth $4,760,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC purchased a new position in shares of Amphastar Pharmaceuticals in the fourth quarter valued at about $2,504,000. Clark Capital Management Group Inc. purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth about $7,560,000. Denali Advisors LLC grew its position in shares of Amphastar Pharmaceuticals by 56.9% during the fourth quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock worth $5,671,000 after purchasing an additional 76,765 shares in the last quarter. Royce & Associates LP raised its stake in Amphastar Pharmaceuticals by 29.4% during the 3rd quarter. Royce & Associates LP now owns 366,322 shares of the company’s stock valued at $9,762,000 after purchasing an additional 83,135 shares during the period. Finally, Algert Global LLC lifted its holdings in Amphastar Pharmaceuticals by 216.1% in the 3rd quarter. Algert Global LLC now owns 392,902 shares of the company’s stock worth $10,471,000 after purchasing an additional 268,612 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $18.33 on Tuesday. The company has a market cap of $808.22 million, a price-to-earnings ratio of 11.04, a PEG ratio of 3.70 and a beta of 0.91. Amphastar Pharmaceuticals, Inc. has a 1 year low of $16.65 and a 1 year high of $31.26. The stock’s 50 day simple moving average is $19.92 and its two-hundred day simple moving average is $23.02. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The firm had revenue of $171.17 million for the quarter, compared to the consensus estimate of $173.46 million. As a group, equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on AMPH shares. Barclays dropped their price target on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a research note on Wednesday, June 3rd. Jefferies Financial Group reissued a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Weiss Ratings lowered shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, April 10th. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 11th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $19.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has a consensus rating of “Reduce” and an average target price of $24.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.